Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1426 - 1430 of 1430

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 602 of 602

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1 - 25 of 25

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1826 - 1850 of 2142

Please scroll or swipe to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Status	Project Number
Saxagliptin + metforminOpens in new tab	Submission Status Report Opens in new tab	Jun 6, 2013	Reimbursement Review	Withdrawn	SR0336-000
CanagliflozinOpens in new tab	Submission Status Report Opens in new tab	Jun 5, 2013	Reimbursement Review	Withdrawn	SR0335-000
SomatropinOpens in new tab	Submission Status Report Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Recommendation and Reasons Opens in new tab	May 27, 2013	Reimbursement Review	Complete	SR0332-000
SomatropinOpens in new tab	Submission Status Report Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Recommendation and Reasons Opens in new tab	May 27, 2013	Reimbursement Review	Complete	SR0333-000
SomatropinOpens in new tab	Submission Status Report Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Recommendation and Reasons Opens in new tab	May 27, 2013	Reimbursement Review	Complete	SR0334-000
Ingenol mebutateOpens in new tab	Submission Status Report Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Recommendation and Reasons Opens in new tab	May 9, 2013	Reimbursement Review	Complete	SR0330-000
LurasidoneOpens in new tab	Submission Status Report Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Recommendation and Reasons Opens in new tab	May 9, 2013	Reimbursement Review	Complete	SR0331-000
RivaroxabanOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab	May 6, 2013	Reimbursement Review	Complete	SR0327-000
Ulipristal acetateOpens in new tab	Submission Status Report Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Recommendation and Reasons Opens in new tab	Apr 17, 2013	Reimbursement Review	Complete	SR0326-000
Velcade for Multiple Myeloma - DetailsOpens in new tab	Provincial Funding Summary Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - pERC Final Recommendation Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - Final Clinical Guidance Report Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - Final Economic Guidance Report Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - pERC Initial Recommendation Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - PAG Feedback on Initial Recommendation Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - Manufacturer (Janssen) Feedback on Initial Recommendation Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - Submitter (CCOHDSG) Feedback on Initial Recommendation Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - Patient Advocacy Group (Myeloma Canada) Feedback on Initial Recommendation Opens in new tab Bortezomib (Velcade) for Multiple Myeloma - Patient Advocacy Group (Myeloma Canada) COI Declarations Opens in new tab	Apr 11, 2013	Reimbursement Review	Complete	PC0016-000
Afinitor for Advanced Breast - DetailsOpens in new tab	Provincial Funding Summary Opens in new tab Everolimus (Afinitor) Advanced Breast - pERC Final Recommendation Opens in new tab Everolimus (Afinitor) Advanced Breast - Final Clinical Guidance Report Opens in new tab Everolimus (Afinitor) Advanced Breast - Final Economic Guidance Report Opens in new tab Everolimus (Afinitor) Advanced Breast - pERC Initial Recommendation Opens in new tab Everolimus (Afinitor) Advanced Breast - PAG Feedback on Initial Recommendation Opens in new tab Everolimus (Afinitor) Advanced Breast - Manufacturer (Novartis) Feedback on Initial Recommendation Opens in new tab Everolimus (Afinitor) Advanced Breast - Patient Advocacy Group (CBCN) COI Declarations Opens in new tab Everolimus (Afinitor) Advanced Breast - Patient Advocacy Group (RethinkBC) COI Declarations Opens in new tab	Apr 11, 2013	Reimbursement Review	Complete	PC0014-000
Inlyta for metastatic renal cell carcinoma (mRCC) - DetailsOpens in new tab	Provincial Funding Summary Opens in new tab Axitinib (Inlyta) for mRCC - pERC Final Recommendation Opens in new tab Axitinib (Inlyta) for mRCC - Final Clinical Guidance Report Opens in new tab Axitinib (Inlyta) for mRCC - Final Economic Guidance Report Opens in new tab Axitinib (Inlyta) for mRCC - pERC Initial Recommendation Opens in new tab Axitinib (Inlyta) for mRCC - PAG Feedback on Initial Recommendation Opens in new tab Axitinib (Inlyta) for mRCC - Manufacturer (Pfizer Canada Inc.) Feedback on Initial Recommendation Opens in new tab Axitinib (Inlyta) for mRCC - Patient Advocacy Group (KCC) Feedback on Initial Recommendation Opens in new tab Axitinib (Inlyta) for mRCC - Patient Advocacy Group (KCC) COI Declarations Opens in new tab	Mar 22, 2013	Reimbursement Review	Complete	PC0013-000
Dabigatran etexilateOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 18, 2013	Reimbursement Review	Complete	SF0320-000
RivaroxabanOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 18, 2013	Reimbursement Review	Complete	SF0321-00
PerampanelOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 8, 2013	Reimbursement Review	Complete	SR0316-000
Azilsartan medoxomilOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 8, 2013	Reimbursement Review	Complete	SR0317-000
Azilsartan medoxomil + chlorthalidoneOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 8, 2013	Reimbursement Review	Complete	SR0318-000
MirabegronOpens in new tab	Submission Status Report Opens in new tab	Mar 8, 2013	Reimbursement Review	Withdrawn	SR0319-000
Interferon beta-1aOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 8, 2013	Reimbursement Review	Complete	SR0298-000
EverolimusOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 8, 2013	Reimbursement Review	Complete	SR0315-000
Zolpidem tartrateOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Mar 7, 2013	Reimbursement Review	Complete	SR0314-000
Treanda for Chronic Lymphocytic Leukemia (First Line)Opens in new tab	Provincial Funding Summary Opens in new tab Bendamustine (Treanda) for CLL (Firstline)- pERC Final Recommendation Opens in new tab Bendamustine (Treanda) for CLL (First Line) - Final Clinical Guidance Report Opens in new tab Bendamustine (Treanda) for CLL (First Line) - Final Economic Guidance Report Opens in new tab Bendamustine (Treanda) for CLL (First Line) - pERC Initial Recommendation Opens in new tab Bendamustine (Treanda) for CLL (First Line) - PAG Feedback on Initial Recommendation Opens in new tab Bendamustine (Treanda) for CLL (First Line) - Manufacturer (Lundbeck Canada) Feedback on Initial Recommendation Opens in new tab Bendamustine (Treanda) for CLL (First Line) - Patient Advocacy Group (CLL PAG) COI Declarations Opens in new tab Bendamustine (Treanda) for CLL (First Line) - Patient Advocacy Group (LLSC) COI Declarations Opens in new tab	Mar 6, 2013	Reimbursement Review	Complete	PC0011-000
TelaprevirOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Feb 19, 2013	Reimbursement Review	Complete	SF0311-000
BoceprevirOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Feb 19, 2013	Reimbursement Review	Complete	SF0312-000
AdalimumabOpens in new tab	Submission Status Report Opens in new tab Recommendation and Reasons Opens in new tab	Feb 4, 2013	Reimbursement Review	Complete	SR0308-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81